Literature DB >> 15369452

Effects of estrogen deprivation due to breast cancer treatment.

N Angelopoulos1, V Barbounis, S Livadas, D Kaltsas, G Tolis.   

Abstract

Breast cancer is one of the main life-threatening diseases that a woman may have to face during her lifetime. The increasing incidence of breast neoplasia reported over the last few decades has led to widespread screening of women resulting in early diagnosis. One common but challenging question for most doctors, after the surgical excision of the lesion, is determination of the ideal adjuvant therapy for their patients for the achievement of maximum life expectancy with the best quality of life. Since the beginning of the last century, the knowledge that breast cancer arises from hormone-responsive tissues has long made use of hormone-blocking agents in the beneficial treatment of breast neoplasia. The discovery of new molecules with endocrine actions has rendered the use of adjuvant therapy in a tailor-made pattern too complicated, as these agents have a different mode of action, different adverse effects and probably different indications. The aim of the present review is to clarify these issues, analyzing the mechanism of action of available drugs and their actions on specific areas of uncertainty: cognitive function, cardiovascular system, urogenital tract, bone metabolism, weight gain, hot flushes and premature menopause. Regarding the efficacy of adjuvant therapy, there has been particular focus on the multiple hormonal-induced consequences of each regimen in order to provide the clinician with the available data for choosing the ideal therapy for the patient.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15369452     DOI: 10.1677/erc.1.00783

Source DB:  PubMed          Journal:  Endocr Relat Cancer        ISSN: 1351-0088            Impact factor:   5.678


  7 in total

1.  Cancer and frailty in older adults: a nested case-control study of the Mexican Health and Aging Study.

Authors:  Mario Ulises Pérez-Zepeda; Eduardo Cárdenas-Cárdenas; Matteo Cesari; Ana Patricia Navarrete-Reyes; Luis Miguel Gutiérrez-Robledo
Journal:  J Cancer Surviv       Date:  2016-02-08       Impact factor: 4.442

2.  Alpha2-adrenoceptor action on cell proliferation and mammary tumour growth in mice.

Authors:  A Bruzzone; C Pérez Piñero; L F Castillo; M G Sarappa; P Rojas; C Lanari; I A Lüthy
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

3.  Design of a randomized controlled trial of Internet-based cognitive behavioral therapy for treatment-induced menopausal symptoms in breast cancer survivors.

Authors:  Vera Atema; Marieke van Leeuwen; Hester S A Oldenburg; Valesca Retèl; Marc van Beurden; Myra S Hunter; Neil K Aaronson
Journal:  BMC Cancer       Date:  2016-11-25       Impact factor: 4.430

Review 4.  Efficacy of the LNG-IUS for treatment of endometrial hyperplasia and early stage endometrial cancer: Can biomarkers predict response?

Authors:  Molly Dore; Sara Filoche; Kirsty Danielson; Claire Henry
Journal:  Gynecol Oncol Rep       Date:  2021-02-19

Review 5.  Prevalence of sexual dysfunction in women with cancer: A systematic review and meta-analysis.

Authors:  Seyedeh Esmat Hosseini; Mahnaz Ilkhani; Camelia Rohani; Alireza Nikbakht Nasrabadi; Raza Ghanei Gheshlagh; Ashraf Moini
Journal:  Int J Reprod Biomed       Date:  2022-02-18

6.  Cognitive behavioral therapy and physical exercise for climacteric symptoms in breast cancer patients experiencing treatment-induced menopause: design of a multicenter trial.

Authors:  Saskia F A Duijts; Hester S A Oldenburg; Marc van Beurden; Neil K Aaronson
Journal:  BMC Womens Health       Date:  2009-06-06       Impact factor: 2.809

7.  Cytotoxic effects of Mangifera indica L. kernel extract on human breast cancer (MCF-7 and MDA-MB-231 cell lines) and bioactive constituents in the crude extract.

Authors:  Al-Shwyeh Hussah Abdullah; Abdulkarim Sabo Mohammed; Rasedee Abdullah; Mohamed Elwathig Saeed Mirghani; Mothanna Al-Qubaisi
Journal:  BMC Complement Altern Med       Date:  2014-06-25       Impact factor: 3.659

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.